Prot #GO28141: A Phase III, Double-Blind, Placebo-Controlled Study Of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAFv600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma

    Project: Research project

    Project Details

    StatusFinished
    Effective start/end date6/20/1312/31/15

    Funding

    • Quintiles, Inc. (Prot #GO28141)
    • Genentech, Inc. (Prot #GO28141)